寻常性银屑病患者血清趋化因子CCL27的检测及临床意义

目的 检测寻常性银屑病患者血清CCL27水平并探讨其临床意义。方法 采用酶联免疫吸附法检测61例寻常性银屑病患者治疗前后和45例健康人血清CCL27水平。结果 61例寻常性银屑病患者血清CCL27水平为（670.02 ± 262.15） ng/L，健康人对照组为（373.10 ± 92.84） ng/L，两组差异有统计学意义（t ＝ 8.18，P ＜ 0.01）。进行期患者血清CCL27水平为（799.94 ± 214.54） ng/L，静止期为（422.57 ± 135.53） ng/L，两组差异有统计学意义（t ＝ 8.39，P ＜ 0.01）。经药物治疗8周后，银屑病患者PASI评分下降70％以上者36例，其CCL27水平明显下降，与治疗前比较，差异有统计学意义（t ＝ 9.95，P ＜ 0.01）；PASI评分下降不足70％者25例，CCL27水平与治疗前比较差异无统计学意义（t ＝ 1.84，P ＞ 0.05）。61例银屑病患者血清CCL27水平与PASI评分呈正相关（r ＝ 0.58，P ＜ 0.01）。结论 寻常性银屑病患者血清CCL27水平明显增高，并与疾病活动性相关。

Increased serum level of chemokine CCL27 in patients with psoriasis vulgaris,and its clinical relevance

Objective To determine the serum level of chernokine CCL27 in patients with psoriasis vulgaris,and to analyse its clinical relevance.Methods A total of 61 patients(40 in progressive stage and 21 in stable stage)with psoriasis vulgaris,with an average disease duration of 37.97±14.34 years,were included in this study.Appropriate thempy was given to these patients.Serum samples were collected from the patients before and after therapy,as well as from 45 healthy human controls.ELISA was applied to examine the serum concentration of CCL27.Clinical severity of psoriasis vulgaris was assessed by psoriasis area and severity index(PASI)score.Results Serum level of CCL27 was 670.02±262.15 ng/L in psoriatic patients,compared to 373.10±92.84 ng/L in the controls(t=8.18.P＜0.01).Increased serum level of CCL27 was observed in patients with progressive psoriasis vulgaris compared to those with stable psoriasis (799.94±214.54 ng/L vs 422.57±135.53 ng/L,t=8.39,P＜0.01).After 8 weeks of therapy,a significant decrease was noticed in the serum level of CCL27 in patients who experienced≥70%reduction in PASI score(t=9.95,P＜0.01).but not in those experiencing a PASI reduction of＜70%(t=1.84,P＞0.05).The serum level of CCL27 was positively correlated with PASI score(r=0.58,P＜0.01).Conclusions The serum level of CCL27 is significantly elevated in patients with psoriasis vulgaris,and it is correlated with the disease severity.